HRD Focus Panel
NGS

BRCA1, BRCA2 and Genomic Scare Score(GSS)

NGS
NGS Assays
Features
Accurate evaluation before PARPi therapy
- Detect SNVs/InDels(BRCA1/2) and Genomic scare score (GSS)
1
- Detect SNVs/InDels(BRCA1/2) and Genomic scare score (GSS)
Automatic and safe data analysis
- Onsite server solution for data security
2
- Onsite server solution for data security
HANDLE technology (One-Tube workflow)
- 5 hours TAT for library preparation with 1 hour hands-on time only
3
- 5 hours TAT for library preparation with 1 hour hands-on time only
Limit of Detection (LoD)
- SNVs/InDels (5%) , 30% tumor content
4
- SNVs/InDels (5%) , 30% tumor content
Local end-to-end solution
- Quick and easy to use in local lab
5
- Quick and easy to use in local lab
Product Description

Background
The Homologous Recombination Repair (HRR) pathway plays an important role in the repair of double-strand breaks, which is a major cause of cancer development. It has been demonstrated that loss of function of HRR genes, Homologous Recombination Deficiency (HRD) is the inability to repair double strand breaks and will cause a higher risk of developing cancer[1-5]. Patients with HRD showed higher responses to poly ADP ribose polymerase inhibitors (PARPi) and platinum-containing therapies[6-7]. HRD Score testing and BRCA1/2 mutations testing have been approved for patient selection for PARPi therapy.

Intended Use

The AmoyDx® HRD Focus Panel is a next-generation sequencing (NGS) based in vitro diagnostic assay intended for qualitative determination of homologous recombination deficiency (HRD) status via detection and classification of single nucleotide variants (SNVs) and insertions and deletions (InDels) in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of the Genomic Scare Score (GSS) which is an algorithmic measurement of genomic instability status, using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumour tissue specimens. The assay is intended to aid in identifying ovarian cancer patients with positive HRD status.

This assay is not automated and is for laboratory professional use only.

Principles of the Procedure

The test kit is based on the Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE) system technology which is an improved Molecular Inversion Probe (MIP) technology to capture the target gene region (Figure 1). The unique molecular identifier (UID) is introduced to both ends of each DNA fragment to trace back to original template for error correction. The library construction time of HANDLE system is 5 hours with 1 hour hands-on time. After quality control (QC), the prepared DNA libraries are sequenced on Illumina sequencing platforms to detect the BRCA1/2 gene mutations and HRD status.


Figure 1. Principle of library construction (HANDLE system)

The probe contains an extension arm and a ligation arm which are complementary to the target gene region. First, the extension arm and ligation arm are anchored to the target gene region, and the DNA is extended from the extension arm to the ligation arm using DNA polymerase. Next, the nicks are connected with the ligase to generate the circular products. The remaining linear probes, single-strand and double-strand nucleic acid are digested with the exonuclease. Finally, the universal PCR amplification is performed to enrich the target libraries.

References
1.  Farmer H, Mccabe N, Lord CJ, Tutt A, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
2.  Walsh CS (2015) Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol 137: 343-350.
3.  Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16: 110-120.
4.  Nicholas Turner ATaAA (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. PERSPECTIVES 4.
5.  McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
6.  Ray-Coquard I (2019) Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med: 2416-2428.
7.  KN M QUADRA: a phase 2, open-label single-arm study to evaluate niraparib in patients with relapsed ovarian cancer in 4th or later line of therapy: results from the BRCAmut subset. 2018 ESMO Congress: 944.

Testing Procedure
Compatible Sample Types:FFPE tissue
Compatible NGS Instrument
NextSeq 550Dx
NovaSeq 6000
NextSeq 550
NextSeq 500
Other Info.

Ordering, please contact sales@amoydx.com.

Product Name Size (test/kit)  Storage
AmoyDx® HRD Focus Panel 20T -20℃
Certificate
BACK
Inquiry
Inquiry
* Required information
Manage your account info
Change your password